Watch ZOMDF. Know when insiders buy.
One email the day a filing lands. Free.
ZOMDF
Zomedica Corp.
0.08
+0.00 +1.28%
USD · close Oct 2
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
59
WATCH · shorts 59
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $77.4MP/E —DIV YIELD —FCF YIELD -17.66%REV TTM $36.9M +30.1%NET INCOME −$18.9MNET CASH $6.7M52W 0.06 – 0.15SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $9.5M | +36.6% | 63.5% | −$4.1M | −$3.8M | — | 0.00 | −$2.6M | $92K | −$2.6M | Aug 5 |
| Q1 2026 · Mar 31 | $8.8M | +35.4% | 62.3% | −$4.9M | −$4.5M | — | 0.00 | −$5.3M | $60K | −$5.3M | Aug 5 |
| Q4 2025 · Dec 31derived | $10.5M | +32.6% | 68.5% | −$5.2M | −$4.5M | — | 0.00 | −$899K | $107K | −$1M | Mar 16 |
| Q3 2025 · Sep 30 | $8.1M | +15.7% | 67.2% | −$6.6M | −$6.1M | — | -0.01 | −$4.7M | $43K | −$4.7M | Nov 4 |
| Q2 2025 · Jun 30 | $7M | +13.6% | 67.0% | −$8M | −$7.4M | — | -0.01 | −$5.4M | $137K | −$5.6M | Aug 5 |
| Q1 2025 · Mar 31 | $6.5M | +3.8% | 67.8% | −$64.5M | −$63.8M | — | -0.07 | −$6.6M | $280K | −$6.9M | Aug 5 |
| Q4 2024 · Dec 31derived | $7.9M | +7.6% | 70.3% | −$8.2M | −$7.2M | — | -0.01 | −$4.5M | $575K | −$5.1M | Mar 16 |
| Q3 2024 · Sep 30 | $7M | +10.2% | 72.3% | −$7.4M | −$6.7M | — | -0.01 | −$4.8M | $1.1M | −$5.9M | Nov 4 |
| Q2 2024 · Jun 30 | $6.1M | — | 71.1% | −$25.1M | −$23.9M | — | -0.02 | −$6.7M | $1.2M | −$7.9M | Aug 6 |
| Q1 2024 · Mar 31 | $6.3M | — | 65.7% | −$10.4M | −$9.2M | — | -0.01 | −$7.6M | $2.3M | −$9.9M | May 15 |
| Q4 2023 · Dec 31derived | $7.3M | — | 69.1% | −$23.1M | −$22.4M | — | -0.03 | −$5M | $2M | −$7M | Mar 13 |
| Q3 2023 · Sep 30 | $6.3M | — | 68.7% | −$5.9M | −$491K | — | 0.00 | −$3M | $6.5M | −$9.5M | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $32M | 67.7% | −$84.4M | −$81.9M | -255.6% | -0.08 | −$17.6M | $567K | −$18.2M | — | — |
| FY2024 · to Dec 31 | $27.3M | 70.0% | −$51.1M | −$47M | -172.2% | -0.05 | −$23.6M | $5.2M | −$28.8M | — | — |
| FY2023 · to Dec 31 | $25.2M | 68.8% | −$43.3M | −$34.5M | -137.1% | -0.04 | −$16M | $11.3M | −$27.3M | — | — |
| FY2022 · to Dec 31 | $18.9M | 71.1% | −$21.9M | −$17M | -89.9% | -0.02 | −$11.7M | $787K | −$12.5M | — | — |
| FY2021 · to Dec 31 | $4.1M | 73.9% | −$21.4M | −$18.4M | -444.8% | -0.05 | −$14.3M | $147K | −$14.4M | — | — |
| FY2020 · to Dec 31 | $0 | — | −$16.8M | −$16.9M | — | -0.05 | −$16.2M | $15K | −$16.3M | — | — |
Every number comes from Zomedica Corp.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.